Systems and methods are provided for generating and applying biomimicry tear film layers to a cornea surface. An example method includes forming a multiple layered tear film that are optically transparent, ultra-thin, and smoothly conforming to cornea surface. The multiple layered tear film can include a biomimicry adhesive layer, a biomimicry aqueous layer, and a biomimicry lipid layer. An atomizer/nebulizer/micronizer can be used to generate and applying the biomimicry tear film layers.

Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.

An electronic smoking article includes a liquid supply including liquid material, a heater operable to heat the liquid material to a temperature sufficient to vaporize the liquid material and form an aerosol, a wick in communication with the liquid material and in communication with the heater such that the wick delivers the liquid material to the heater, and at least one air inlet operable to establish a predetermined resistance to draw under a prescribed test of said smoking article.

The present invention provides means and methods for delivering a predetermined volume of a substance, within at least one body cavity of a subject, comprising a predefined volume for containing the predetermined volume of the at least one substance; a delivery end for placement in proximity to the body cavity; the delivery end comprises at least one orifice of diameter D [mm]; a valve mechanically connectable to the container, characterized by at least two configurations: (i) an ACTIVE CONFIGURATION in which the valve enables delivery of predetermined volume V.sub.sub [ml] of the substance; and, (ii) an INACTIVE CONFIGURATION, in which the valve prevents delivery of the predetermined volume V.sub.sub [ml] of the substance from the container to the body cavity; and a fluid tight chamber configured to contain predetermined volume V.sub.gas [ml] of pressurized gas at a predetermined pressure, P.sub.gas [barg].

An in-line droplet delivery device and related methods for delivering precise and repeatable dosages to a subject for pulmonary use is disclosed. The in-line droplet delivery device includes a housing, a mouthpiece, a reservoir, an ejector mechanism, and at least one differential pressure sensor. The in-line droplet delivery device is automatically breath actuated by the user when the differential pressure sensor senses a predetermined pressure change within housing. The in-line droplet delivery device is then actuated to generate a plume of droplets having an average ejected particle diameter within the respirable size range, e.g, less than about 5-6 m, so as to target the pulmonary system of the user. the droplet delivery device is configured in an in-line orientation in that the housing, its internal components, and various device components (e.g., the mouthpiece, air inlet flow element, etc.) are orientated in a substantially in-line or parallel configuration (e.g., along the airflow path) so as to form a small, hand-held device.

A cartridge for a non-burning type flavor inhaler including a flow path forming body having a shape extending along a predetermined direction to form an aerosol flow path, an outer frame having a shape extending along the predetermined direction to accommodate the flow path forming body, a reservoir that is configured to retain an aerosol source, is positioned on the periphery of the flow path forming body in a cross section orthogonal to the predetermined direction and is positioned in a gap between the flow path forming body and the outer frame and an end cap that closes the gap from the downstream side, wherein an outer edge of the end cap contacts an inner wall surface of the outer frame in the cross section orthogonal to the predetermined direction and wherein an inner edge of the end cap is positioned between the outer edge of the flow path forming body and the inner edge of the flow path forming body in the cross section orthogonal to the predetermined direction.

A process and a metered dose inhaler, comprising: an air actuator comprising at least one inlet of liquefied gas (LG), at least one air outlet, at least one first LG-expanding volume and at least one second air-containing volume, the first and second volumes are effectively separated by means of a LG-blocking member; a container with an LG source; said container is in a fluid connection with said LG-expanding volume via the at least one LG inlet; The air actuator is facilitating a metered dose airflow by allowing the expansion of said LG in said at least one LG-expanding volume from its condensed liquid phase to its expanded gas phase. The expansion of said LG facilitates the compression of the air within said at least one air-containing volume, such that a metered dose LG-free air flow is inhalable via at least one air outlet.

The present invention provides a plasma aerosol inhalation device and a method for thinning the sputum. Various radicals generated by plasma can be inhaled in an aerosol form and delivered to the respiratory system for desired efficacy.

One embodiment describes an insulin formulation that is specifically adapted for aerosolization. The formulation comprises a major amount of water and a minor amount of insulin. Further, the formulation is preservative free, without meta-cresol, cresol or phenol, to permit the formulation to be aerosolized using a vibrating aperture plate without substantial foaming of the insulin formulation.

A delivery device for and method of delivering substance, the delivery device comprising: an outlet member through which substance is in use delivered in an entraining gas flow; and a substance supply unit for supplying substance to be entrained by an entraining gas flow as one or both of a vapor or a fine aerosol mist, wherein the substance supply unit comprises a flow channel which is fluidly connected to the outlet member, and a substance supporting element for supporting substance, at least a surface of which is in use disposed in the flow channel.